Brief: Orexo Announces Positive Topline Results From Clinical Study
Jan 10 (Reuters) - Orexo AB ORX.ST :
* ANNOUNCES POSITIVE TOPLINE RESULTS FROM CLINICAL STUDY
OX640-002
* SYSTEMIC SAFETY WAS IN LINE WITH KNOWN PHARMACOLOGY OF
EPINEPHRINE AND LOCAL EFFECTS WERE TRANSIENT AND TOLERATED
* THERE WERE NO SEVERE OR SERIOUS ADVERSE EVENTS
Source text: ID:nMFN9C1M6Y
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens